The maker of blockbuster drugs Wegovy and Ozempic sees its stock plunge 18% after slashing profit forecasts, citing unprecedented competition, patent expiries, and a landmark U.S. pricing deal.
New data reveals a sharp 57% year-on-year drop in Tesla's UK registrations for January, with BYD outselling the US automaker by more than double. The figures highlight intensifying competition in the British electric vehicle market.
A recent bilateral trade deal has slashed Canada's tariff on Chinese electric vehicles from 100% to 6.1%, creating a potential beachhead for China's auto industry in North America amidst ongoing regional trade tensions.
Apeiron Labs, a marine robotics startup, has raised $9.5 million in Series A funding to scale production of its low-cost autonomous underwater vehicles. The company aims to create persistent, detailed monitoring networks beneath the ocean's surface, serving both commercial and defense sectors with data that has traditionally been costly and slow to obtain.
In a landmark move to boost efficiency and extend the life of its aging fleet, Union Pacific has inked a $1.2 billion agreement with Wabtec to modernize 1,700 locomotives—the largest such deal in rail industry history.
Amcor's latest earnings reveal surging sales in pharmaceutical packaging, driven by demand for GLP-1 medications, while the company outlines cost savings from its Berry Global integration including over 600 job cuts and 20 site closures.
New research reveals that while consumers are eager for novel private-label products, deep discounts remain the most powerful catalyst to overcome purchase hesitation and drive trial.
The Trump administration is pulling 700 federal immigration officers out of Minnesota following weeks of contentious enforcement actions and the fatal shootings of two protesters. Officials cite improved coordination with local jails, but a significant federal contingent remains.
Barclays and Scotiabank have raised their price targets for Teva Pharmaceutical following its better-than-expected Q4 2025 results and a key pediatric approval for its migraine drug AJOVY, signaling growing confidence in the generic drugmaker's turnaround trajectory.
Graphic Packaging International reported a significant drop in fourth-quarter and full-year 2025 profits, with net income falling 48% and 33% respectively. The packaging giant faces pressure from consumer affordability issues and competitive markets, prompting a strategic review by its newly appointed CEO.
The Washington Post has initiated a significant strategic reset, resulting in widespread layoffs and the closure or restructuring of several key departments, including Sports and Books, as the news organization grapples with a challenging media landscape.
A sharp drop in network competition and growing investor enthusiasm for high-performance computing ventures propelled U.S.-listed bitcoin miners to a strong January rally, even as bitcoin prices softened, according to a new JPMorgan analysis.
Citi analysts report Bitcoin is trading below the average cost basis of U.S. spot ETF holders and nearing a key pre-election price floor, as fading institutional inflows and macro headwinds pressure the cryptocurrency market.
A temporary spending bill has averted a full government shutdown, but funding for the Department of Homeland Security remains in limbo. With a one-week deadline, lawmakers are locked in a contentious debate over reforming ICE and Border Patrol tactics, while a new study underscores immigrants' fiscal contributions to the U.S. economy.
Federal immigration authorities will significantly reduce their operational footprint in Minneapolis, citing enhanced cooperation with local jails and officials that allows for a more targeted approach.
The Danish pharma giant reported strong 2025 results driven by its blockbuster obesity and diabetes drugs but forecast a challenging 2026 due to pricing pressures and looming patent expiries, even as it rolls out a pivotal new oral weight-loss treatment in the U.S.
Following a year of record production, Norwegian energy giant Equinor signals a strategic pivot, scaling back capital expenditure in renewables and low-carbon projects for 2026-27 while reaffirming core fossil fuel growth and robust shareholder distributions amidst market volatility.
Investment firm Lake Street Capital Markets has lowered its price target for Aquestive Therapeutics to $6, down from $8, while maintaining a Buy rating. The adjustment follows the company's receipt of a Complete Response Letter from the FDA for its epinephrine film Anaphylm, delaying its potential market launch.
Microchip Technology introduces the MCPF1525, a compact, high-density power module designed to meet the escalating energy demands of AI data centers. The stackable device promises significant space savings and advanced programmability for powering PCIe switches and compute MPUs.
While PPL's stock has trailed the broader market over the past year, recent quarterly beats and a stable regulatory profile have analysts maintaining a 'Moderate Buy' stance, albeit with tempered near-term expectations.
